Background: Community pharmacists are well positioned to support patients' minor ailments. The objective was to evaluate the clinical and humanistic impact of a minor ailment service (MAS) in community pharmacy compared with usual pharmacist care (UC).
Methods: A cluster randomised controlled trial was conducted. Intervention patients received MAS, which included a consultation with the pharmacist. MAS pharmacists were trained in clinical pathways and communication systems mutually agreed with general practitioners and received monthly support. Control patients received UC. All patients were followed up by telephone at 14 days. Clinical and humanistic impact were defined by primary (appropriate referral rate and appropriate non-prescription medicine rate) and secondary outcomes (clinical product-based intervention rate, referral adherence, symptom resolution, reconsultation and EuroQol EQ-5D visual analogue scale (VAS)).
Results: Patients (n=894) were recruited from 30 pharmacies and 82% (n=732) responded to follow-up. Patients receiving MAS were 1.5 times more likely to receive an appropriate referral (relative rate (RR)=1.51; 95% CI 1.07 to 2.11; p=0.018) and were five times more likely to adhere to referral, compared with UC (RR=5.08; 95%CI 2.02 to 12.79; p=0.001). MAS patients (94%) achieved symptom resolution or relief at follow-up, while this was 88% with UC (RR=1.06; 95% CI 1 to 1.13; p=0.035). MAS pharmacists were 1.2 times more likely to recommend an appropriate medicine (RR 1.20, 95% CI 1.1 to 1.3; p=0.000) and were 2.6 times more likely to perform a clinical product-based intervention (RR=2.62, 95% CI 1.28 to 5.38; p=0.009), compared with UC. MAS patients had a greater mean difference in VAS at follow-up (4.08; 95% CI 1.23 to 6.87; p=0.004). No difference in reconsultation was observed (RR=0.98; 95% CI 0.75 to 1.28; p=0.89).
Conclusion: The study demonstrates improved clinical and humanistic outcomes with MAS. National implementation is a means to manage minor ailments more effectively in the Australian health system.
Trial Registration Number: ACTRN12618000286246.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bmjqs-2019-010608 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of dioscin from Dioscorea nipponica on TL1A/DR3 and Th9 cells in a collagen-induced arthritis mouse model.
Int Immunopharmacol
January 2025
Department of Anatomy, Basic Medical Institute, Chengde Medical University, Chengde 067000 Hebei, China. Electronic address:
Rheumatoid arthritis (RA) is a systemic autoimmune disease, and TL1A and its receptor DR3 play important roles in its pathogenesis. Th9 cells are involved in RA development. Dioscin from Dioscorea nipponica (DDN) has a therapeutic effect on RA, but its effect on TL1A/DR3 and Th9 cells remains unclear.
View Article and Find Full Text PDFEffects of Animal-Assisted Therapy for Anxiety Reduction in Children and Adolescents: A Systematic Review.
J Clin Med
January 2025
Institute of Psychology and Neuropsychology of Porto-IPNP Health, 4000-055 Porto, Portugal.
: Animal-Assisted Therapy (AAT) is a clinical approach aimed at building valuable human-animal relationships with both preventive and therapeutic goals. It is provided by a healthcare professional and involves animals (meeting certain criteria) as an integral part of the treatment process. This type of therapy has been shown to have multiple benefits in several areas, such as reducing anxiety in a variety of different groups of people.
View Article and Find Full Text PDFThe preventive effect of psychological and psychosocial interventions on postpartum depression: An overview of systematic reviews.
J Psychiatr Res
November 2024
Innovation Center of Humanistic Care and Health Management, School of Nursing, Hebei Medical University, Shijiazhuang, Hebei Province, China. Electronic address:
Background: Postpartum depression is a prevalent issue that significantly impacts the mental health of women, placing a substantial burden on individuals, families, and society. With the increasing evidence of postpartum depression prevention, conducting comprehensive assessments becomes essential to facilitate future clinical practices.
Methods: The systematic review and meta-analysis examined psychological and psychosocial interventions to prevent postpartum depression in perinatal women (antenatal and postnatal up to 12 months).
Guidance for an Effective Approach to Integrated Evidence Planning in a Dynamic World.
Clin Pharmacol Ther
January 2025
Boston Consulting Group, Zurich, Switzerland.
The value of a medicine is defined by its impact on patients, caregivers, health system, and society. A pharmaceutical company will generate evidence to demonstrate this value in various studies, including randomized clinical trials, non-interventional and observational studies, real-world data analyses, modeling, and simulation. The quality and strength of the evidence supporting a medicine's effectiveness, safety and product quality will drive decisions by healthcare system stakeholders for marketing authorization (regulatory authorities).
View Article and Find Full Text PDFThe burden of X-linked retinitis pigmentosa (XLRP) on patient experience and patient-reported outcomes (PROs): findings from the EXPLORE XLRP-2 study.
Eye (Lond)
January 2025
Janssen-Cilag GmBH, Neuss, Germany.
Background/aims: X-linked retinitis pigmentosa (XLRP) is considered one of the most severe forms of retinitis pigmentosa (RP), accounting for 5-15% of all RP cases and primarily affecting males. However, the real-world humanistic impacts of this disease on patients are poorly investigated, especially with respect to burdens faced by patients with varying disease severities.
Methods: EXPLORE XLRP-2 was an exploratory, multicentre, non-interventional study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!